Stockscreener 앱 받기
2.15
1.83%
-0.04
시간 외 거래:
2.66
0.51
+23.72%
Gt Biopharma Inc 주식(GTBP)의 최신 뉴스
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
GT Biopharma Announces Recently Presented Data on Our Next Generation TriKE (OXS-C3550) at The Ash Meeting in Atlanta, GA - ACCESS Newswire
Nanobodies Market Analysis: Growth Drivers in Targeted - openPR
Pre-market Movers In Healthcare Sector: HUGE, ONTX, SVRA, CELC, CHFS... - RTTNews
StockNews.com Initiates Coverage on Beasley Broadcast Group (NASDAQ:BBGI) - Defense World
StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS) - Defense World
Barnes Group (NYSE:B) Now Covered by StockNews.com - Defense World
Apollo Commercial Real Estate Finance (NYSE:ARI) Stock Rating Lowered by StockNews.com - Defense World
First Financial Bancorp Reports Solid Financial Performance in Fourth Quarter 2024 - Defense World
StockNews.com Begins Coverage on Power REIT (NYSE:PW) - Defense World
Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com - Defense World
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded by StockNews.com to Hold Rating - Defense World
Goldman Sachs Announces Adoption of Tax Benefit Preservation Plan - Defense World
Seaport Res Ptn Forecasts Weaker Earnings for Sands China - Defense World
Galectin Therapeutics Inc. Reports Results from 2024 Annual Meeting in Recent 8-K Filing - Defense World
Cormark Weighs in on Real Matters’ FY2025 Earnings (TSE:REA) - Defense World
AmpliTech Group, Inc. (NASDAQ:AMPG) Short Interest Down 60.9% in January - Defense World
GT Biopharma Announces First Patient Dosed in Phase 1 Trial - GlobeNewswire
GT Biopharma, Inc. Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies - Marketscreener.com
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies - The Manila Times
GT Biopharma Initiates Phase 1 Trial of Advanced TriKE Therapy for Blood Cancers - StockTitan
GT Biopharma and Cytovance Biologics Announce Collaboration Agreement TriKE(TM) Therapeutic for Treatment of Coronavirus Infection - ACCESS Newswire
Nanobodies Market Generated Opportunities, Future Scope - openPR
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
Nanobodies Market reached US$ 502.60 million in 2023 and - openPR
Biotech Stocks Surging in September - AccessWire
Maryland Biotech Gains Regulatory Approval - Streetwise Reports
GT Biopharma files automatic mixed securities shelf - MSN
FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace
Stock market today: Traws Pharma +231.47%, Rumble +59.02% among top gainers in early trading - Business Upturn
First Heartland Consultants Inc. Sells 10,222 Shares of Amazon.com, Inc. (NASDAQ:AMZN) - Defense World
Nk Cell Therapy Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeut - Barchart
GTBP Stock Hits 52-Week Low at $1.92 Amid Market Challenges - Investing.com
New Data Supports BLA Package - Streetwise Reports
Contrasting GT Biopharma (NASDAQ:GTBP) and Allakos (NASDAQ:ALLK) - Defense World
The Goodyear Tire & Rubber Company (NASDAQ:GT) Shares Acquired by Fmr LLC - Defense World
BeautyHealth Releases 2024 Skintuition Report - Quantisnow
Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says - Streetwise Reports
California Biopharma Shows Promising Phase 1 Data - Streetwise Reports
Nanobodies Market Is Booming Worldwide 2024-2031 | Merck KGaA, - openPR
Drug Trial Shows Positive Interim Results for ALS Treatment - Streetwise Reports
FDA Decision on Drug for Bone Marrow Due Early 2025 - Streetwise Reports
Roth Capital Weighs in on GT Biopharma FY2024 Earnings - Defense World
United States Nanobodies Market Size, Trends, Growth, - openPR
1.03%
자본화:
|
볼륨(24시간):